JDRF Centre of Excellence at the University of British Columbia

JDRF Campaign to Accelerate

We started with a vision. How do we accelerate research towards cures for type 1 diabetes (T1D)? How do we make the biggest impact? This vision anchored our thinking to build a campaign that focused on maximizing impact, speeding up our research and leveraging partners to accomplish this. Now is the time to accelerate.

Our six fundraising priorities provide a framework for attacking T1D from every angle. The JDRF Centre of Excellence at the University of British Columbia is a key pillar of our $100 Million Campaign to Accelerate.

 

JDRF Centres of Excellence – A Global Collaboration to Fuel Discovery

Across the country and around the world, leading scientists are working to solve the many parts of the T1D puzzle to deliver cures and life-improving breakthroughs. In some places, the research underway is so deep and so rich that it warrants particular focus. It is in these areas that we are launching JDRF Centres of Excellence.

 

What is a Centre of Excellence?

JDRF Centres of Excellence provide a research funding model that fosters highly dynamic, nimble work to drive discovery with maximum speed. In contrast to conventional research grants, a Centre of Excellence brings together a large team of experts from diverse fields – and recruits new talents – to accelerate T1D advances through a collaborative approach.

This model is also a highly cost-effective way of advancing research because it leverages and streamlines existing research facilities and talent. By removing the capital costs of developing a new physical space, the Centre of Excellence model ensures that donor dollars are directed to research rather than overhead. With a gold-standard peer-review process and transparent governance, JDRF globally maintains a 360-degree view of the work of all its Centres to prioritize the science that holds the most promise for the T1D community.

Vancouver will be home to the first JDRF Centre of Excellence in Canada, joining other locations featured in the graphic below as one of just five Centres worldwide.

“Each Centre takes a different approach to some of the biggest problems that we face, but the line of sight is to find solutions for people with T1D.”

-Dr. Aaron Kowalski, CEO, JDRF International

“By getting these collaborations going, we’re able to leverage facilities that already exist, so we’re focusing on the research and not having to build the infrastructure.”

-Dave Prowten, CEO, JDRF Canada

“They’re not just five independent Centres. Together they will be covering a portfolio of scientific challenges that are core to our global strategic plan.”

-Mike Wilson, CEO, JDRF Australia

 

Leadership in Vancouver

The JDRF Centre of Excellence at the University of British Columbia (UBC) unites the expertise of global research leaders and partnerships in industry, health care, government, and academia towards a singular goal: curing T1D. The Centre creates an environment for sustained multidisciplinary collaboration between three key sites – UBC’s Life Sciences Institute, BC Children’s Hospital Research Institute (BCCHRI), and Vancouver General Hospital (VGH) – allowing for rapid progress and efficiently translation of discoveries in the lab to clinical solutions for people living with T1D.

The goal of the Centre’s research team is to bring two or more solutions to cure or slow the progression of T1D to the clinical testing stage within just five years. These discoveries may also uncover therapeutic approaches for other diseases.

The Centre’s research leads are:

Dr. Bruce Verchere, BCCHRI and UBC

Expertise: beta cell physiology and beta cell regeneration

Dr. Verchere’s work has led to the discovery of new beta cell biomarkers and the discovery of promising approaches to slow immune attack in T1D and islet transplants. He has served as a close JDRF International advisor for many years.

Dr. Megan Levings, BCCHRI and UBC

Expertise: immunology, autoimmunity and cellular therapy

Dr. Levings’ work has informed the rationale for an ongoing phase 2 clinical trial of an immunotherapy agent in young people with T1D. She developed new ways to monitor immune system activity and created a new immune cell therapy approach to limit the autoimmune response.

Dr. James Johnson, UBC

Expertise: fundamental biology of pancreatic islets, insulin action

Dr. Johnson has extensive experience in beta cell biology, including in target discovery and development of drugs for diabetes. He is also Editor-in-Chief of the scientific journal Islets.

Dr. Francis Lynn, BCCHRI and UBC

Expertise: beta cell biology, molecular biology, physiology

Dr. Lynn has uncovered the roles of several key regulators of beta cell differentiation and proliferation that have informed strategies for beta cell regeneration and replacement. He is also an expert in the gene editing techniques being explored to create “designer” beta cells.

Dr. Sarah Linklater, Chief Scientific Officer, JDRF Canada

Expertise: diabetes, autoimmunity and immune regulation, scientific and medical publishing, knowledge translation

Dr. Linklater leads JDRF Canada’s research strategy, funding programs and partnerships, and also oversees all clinical trials and research projects funded by the organization in Canada. She acts as the central liaison for research-related matters with JDRF International and Canadian researchers. Sarah holds a PhD in Experimental Medicine and served as Editor-in-Chief of The Lancet Diabetes & Endocrinology in the UK before joining JDRF Canada.

In addition to the research leads, more than 35 other researchers, trainees, technical staff and collaborators will be involved in driving the Centre’s research projects.

 

 

Research goals

T1D involves dysfunction of both the immune system and pancreatic beta cells, yet these are often studied in isolation, hindering real progress. The JDRF Centre of Excellence at UBC brings together world-leading expertise from both domains and proposes research that requires integrated study of the immune system and beta cells and their complex interactions. Research teams will be laser-focused on finding cures through three integrated and interdependent themes:

  1. Developing a new source of insulin-producing beta cells
  • Accelerate the development of a new, cost-effective cell therapy product that will provide long-lasting insulin independence with transplantation.
    Watch the video to learn more.
  1. Protecting insulin-producing beta cells from immune attack 
  • Develop and test several innovative approaches to stop and reverse the immune response that causes harm to insulin-producing beta cells in people with T1D, without using generalized immunosuppression.
    Watch the video to learn more.
  1. Targeting and monitoring beta cell stress
  • Measure and modulate the beta cell stress response that contributes to T1D to stop disease progression or even prevent it.
    Watch the video to learn more.

 

The JDRF Centre of Excellence at the University of British Columbia, set to launch Winter 2021, will be a gamechanger. It will accelerate research, deliver breakthroughs, and help secure a future without T1D.

 

 

Donors Provide Visionary Support

JDRF is grateful to the generous donors who have supported the JDRF Centre of Excellence with leadership gifts. These individuals, foundations, and corporations are helping our research team aggressively pursue the most promising research – and speed its progress through the pipeline so that it reaches people living with T1D as quickly as possible.

Join us in Finding A Cure

If you would like to learn more about how you can support this pillar of our $100 Million Campaign to Accelerate, and help defeat the monster we know as T1D, please contact Nicole Robson at 604-292-2779 or nrobson@jdrf.ca. Contact us